Axonics, Inc. (NASDAQ:AXNX) Short Interest Update

Axonics, Inc. (NASDAQ:AXNX) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 3,310,000 shares, a growth of 5.4% from the October 15th total of 3,140,000 shares. Based on an average daily trading volume, of 388,400 shares, the short-interest ratio is currently 8.5 days.

Insider Buying and Selling at Axonics

In other Axonics news, CFO Kari Leigh Keese sold 2,961 shares of Axonics stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $69.41, for a total value of $205,523.01. Following the completion of the transaction, the chief financial officer now owns 40,362 shares of the company’s stock, valued at approximately $2,801,526.42. The trade was a 6.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.85% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Janney Montgomery Scott LLC acquired a new stake in shares of Axonics in the first quarter valued at $218,000. Swiss National Bank increased its position in Axonics by 0.6% in the 1st quarter. Swiss National Bank now owns 100,000 shares of the company’s stock valued at $6,897,000 after acquiring an additional 600 shares during the period. ProShare Advisors LLC increased its holdings in shares of Axonics by 54.9% in the first quarter. ProShare Advisors LLC now owns 12,752 shares of the company’s stock valued at $880,000 after purchasing an additional 4,517 shares during the period. Edgestream Partners L.P. purchased a new position in Axonics during the 1st quarter worth $605,000. Finally, Gamco Investors INC. ET AL purchased a new position in Axonics during the first quarter worth about $2,015,000. Institutional investors and hedge funds own 99.48% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reiterated a “hold” rating on shares of Axonics in a research report on Friday, November 8th. Eight investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $71.00.

Axonics Stock Performance

NASDAQ AXNX opened at $70.98 on Tuesday. The stock has a market cap of $3.63 billion, a PE ratio of -591.45 and a beta of 0.82. The stock has a fifty day simple moving average of $69.91 and a 200-day simple moving average of $68.63. Axonics has a twelve month low of $55.09 and a twelve month high of $71.05.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.